Integrated Research Reports 16% Revenue Drop and $2.1m EBITDA Loss in FY26
Integrated Research’s FY26 results reveal a sharp 91% drop in net profit amid softer renewals and rising expenses, offset by a 27% jump in cash and a special dividend. The company pushes forward with AI-powered products despite early-stage commercialisation risks.
- Net profit plunges 91% to $1.21 million
- Revenue falls 16% to $57.6 million amid weaker renewals
- Expenses rise 7%, driven by a $5 million credit loss provision
- Strong cash balance up 27% to $51.7 million supports innovation
- AI product launches mark early steps in new growth strategy
Profit Collapse Amid Renewals Softness and Credit Losses
Integrated Research Limited (ASX:IRI) reported a startling 91% plunge in net profit to just $1.21 million for FY26, a steep fall from $13.4 million the previous year. Revenue dropped 16% to $57.6 million, hit by a softer renewals book and a slowdown in new business during the second half. The company’s EBITDA swung to a loss of $2.1 million, reflecting the combined impact of lower sales, a $5 million expected credit loss provision largely tied to a single client, and adverse foreign currency movements.
Despite these setbacks, cash generation remained robust, with cash reserves swelling 27% to $51.7 million. This strong balance sheet underpinned a fully franked final dividend hike to 5 cents per share, including a special dividend of 2 cents, rewarding shareholders amid challenging trading conditions.
Geographical and Product Revenue Trends
Regionally, the Americas accounted for the lion’s share of revenue at $41.3 million but declined 14% year-on-year, while Asia Pacific revenue tumbled 29% to $11 million. Europe was the sole bright spot, growing 13% to $5.3 million. The product mix reflected uneven performance: Collaborate revenues fell 27% due to a weaker renewals base, Infrastructure declined 19%, but Transact grew 18% driven by early renewals with multi-year contracts averaging 3.2 years.
AI Investment and Product-Led Growth Strategy
Integrated Research is doubling down on its product-led growth strategy, heavily investing in AI and machine learning capabilities through its dedicated innovation arm, IR Labs. FY26 saw the beta release of its first standalone AI product aimed at automating software quality assurance, alongside the launch of Iris, a natural language AI interface integrated into its Prognosis platform, and Elevate, a cloud-hosted SaaS offering designed to simplify deployment.
These AI-driven innovations are early in their lifecycle and have yet to contribute materially to revenue, introducing commercialisation risks. Nevertheless, the company sees AI both as a disruptor and an enabler, with client demand evolving towards shorter contract terms and more cautious investment amid rapid technology change.
Cost Management and Credit Challenges
Operating expenses rose 7% to $58.8 million, driven largely by a $5 million increase in credit loss provisions, a marked jump from $0.1 million the prior year. This provision relates principally to delinquent receivables from a single client contract and weighed heavily on profitability. Product and technology expenses surged 29% to $17.4 million, reflecting the company’s strategic pivot towards innovation and new product development, representing 30% of total revenue.
Executive Remuneration and Governance
CEO Ian Lowe, appointed in October 2024, received a short-term incentive payout of 42% of target, reflecting partial achievement of challenging FY26 objectives amid a tough operating environment. Long-term incentives remain contingent on achieving a 10% compound annual growth rate in underlying earnings per share over three years. The board increased director fees by 3% and maintained a disciplined approach to governance and risk management, including detailed oversight of AI product commercialisation and market risks.
Market Conditions and FY27 Priorities
The company noted lengthening sales cycles and shorter average contract durations, attributed largely to AI-driven disruption and heightened client caution. FY27 priorities focus on accelerating monetisation of AI-enabled offerings, expanding client engagement, and continuing disciplined investment in product innovation. The renewals book for FY27 is weighted towards the second half, suggesting potential for revenue recovery later in the year.
Integrated Research’s strong cash position and established client base provide a platform for navigating ongoing market uncertainty, though risks remain around AI adoption pace, procurement delays, competitive pressures, and foreign exchange volatility. How swiftly the company converts its AI investments into sustainable revenue streams will be critical to watch in the coming quarters.
Bottom Line?
Integrated Research faces a pivotal FY27 as early AI product investments collide with cautious enterprise spending and credit risks, testing its path to sustainable growth.
Questions in the middle?
- Will AI-enabled products gain traction fast enough to offset renewals softness and credit losses?
- How will extended enterprise procurement cycles impact new contract signings in FY27?
- Can Integrated Research maintain its strong cash position while balancing innovation investment and profitability?
